Interleukin 22, a Potential Therapeutic Target for Rheumatoid Arthritis

To the Editor:

A recent report by Da Rocha, et al indicated that levels of interleukin 22 (IL-22) were increased in patients with rheumatoid arthritis (RA) compared with controls; levels of IL-22 correlated with Disease Activity Score (DAS28) and Clinical Disease Activity Index measures, rheumatoid factor positivity was correlated with higher levels of IL-22 in patients with RA, and the presence of bone erosions was associated with high IL-22 levels. These findings suggest that IL-22 may be a good biomarker for assessment of activity in RA, and IL-22 seems to be a potential therapeutic target for RA.

Other studies have indicated the similar relationship between IL-22 and RA, where serum IL-22 levels were found to be increased in patients with RA compared with controls and high IL-22 levels correlated with bone erosions. The IL-22 concentration in synovial fluid was higher in patients with RA compared with control patients. In patients with RA, Th17 cells were recognized to produce higher IL-22. Th22 cells also produced IL-22 and the expression of Th22 cells. IL-22 were significantly elevated in RA patients. More importantly, Th17/22 cells showed positive correlations with IL-22, C-reactive protein, and DAS28 data. In addition, natural killer (NK)-22 cells in vitro can secrete higher levels of IL-22 and tumor necrosis factor-α (TNF-α), and NK-22 supernatant can induce the proliferation of RA fibroblast-like synoviocytes (FLS); however, addition of IL-22 antibody plus TNF-α antibody inhibited the proliferation of FLS induced by the NK-22 supernatant. In vitro, human recombinant IL-22 (rhIL-22) significantly increased proliferation of RA synovial fluid and FLS and production of monocyte chemotactic protein-1, but an inhibitory effect of anti-IL-22R antibody on proliferation of FLS induced by rhIL-22 was found in RA1. Moreover, an experimental arthritis model (IL-1Ra−/−) demonstrated that IL-22 in the sera of IL-22−/− mice was less susceptible to CIA than wild-type mice, as shown by their reduced incidence of arthritis and decreased pannus formation. Remarkably, the less severe form of arthritis in IL-22−/− mice was associated with increased production of collagen II-specific and total IgG antibodies. In vitro, IL-22 was found to promote osteoclastogenesis, a process that may contribute to its proinflammatory activity in CIA10. On the other hand, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) prevented corticosteroid-induced osteoporosis in patients with early RA, where 1,25(OH)2D3 directly modulated human Th17 polarization, accompanied by suppression of IL-17, TNF-α, and IL-22 production11. In patients with RA, rituximab reduced expression of IL-22 and Th17-positive cells in synovial tissue, and this correlated with better clinical outcomes. In vitro, rituximab strongly reduced IL-17 and IL-22 production induced by Candida albicans12.

These findings suggest therapeutic potential for patients with RA, and suggest a role for IL-22 in development of RA. Further studies are needed to clarify the role of IL-22 in RA. Therapeutic agents targeting IL-22 might result in innovative new therapies for RA.

REFERENCES


J Rheumatol 2012;39:11; doi:10.3899/jrheum.120757

QIANG XIE, MD, School of Pharmacy, Anhui Medical University, PET/CT Center, Anhui Provincial Hospital; SHI-CUN WANG, MM, PET/CT Center, Anhui Provincial Hospital; JUN LI, MD, School of Pharmacy, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, PR China. Address correspondence to Dr. Li; E-mail: lijun@ahmu.edu.cn

Downloaded on October 18, 2022 from www.jrheum.org